Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease
about
Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in miceAntibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing)Common variable immunodeficiency presenting as herpes simplex virus encephalitis.Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.Pathogenesis of herpes simplex virus-induced ocular immunoinflammatory lesions in B-cell-deficient mice.Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro.Localization of a passively transferred human recombinant monoclonal antibody to herpes simplex virus glycoprotein D to infected nerve fibers and sensory neurons in vivo.Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display librariesAnalysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein BHerpes virus fusion and entry: a story with many characters.Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virusEffect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virusRecombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitroImmunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2.Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody responseEntry of herpes simplex virus 1 in BJ cells that constitutively express viral glycoprotein D is by endocytosis and results in degradation of the virusFine mapping of antigenic site II of herpes simplex virus glycoprotein DHumoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine.Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicityAntigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeuticsExpression of herpes simplex virus type 1 glycoprotein D deletion mutants in mammalian cellsAntigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutantsInduction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blottingProtection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitisEpitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sitesLocalization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody.Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia.Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2.Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytesComparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice.Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody.
P2860
Q27486805-D1D6C1C0-5E45-4154-AEB1-224B51B29717Q27486833-E95EE456-8A88-4BAF-80CF-8DAF55A868D5Q30428549-32B9B2A1-18F4-4989-A69E-B0856500C26AQ33603438-E77BFAB3-2F85-4F14-8E93-6966F1701382Q33625030-6D32F740-A125-4A90-A88A-7728C84AD935Q33802025-61CC21A0-3F50-4953-B353-9D98CF57DFA0Q33815811-A5D9D90E-675C-4B8C-A900-8FDB7C69A183Q33821358-1135906A-4D00-4F43-B031-0D6617B634BAQ34127099-A156DC31-F2CA-4B27-AF63-152BA73D35D2Q34256508-9792CFE6-E31E-4117-8238-BF54ED648230Q34285628-99758632-8A79-400A-9BDB-C57BB3C650B1Q34529794-699C23F8-0A2D-48E4-B6BB-89D165AB418EQ34605155-AE1CAB6F-5707-4135-978A-61BCE74F5444Q34959913-B99E7E8D-0AD9-4D6E-BD15-1AFD9C7DC290Q35882585-90649964-D22C-4926-BAB1-F0E09507021AQ36333640-717729D5-DDC2-4355-84DB-B98BB3F300A9Q36335255-50D81814-C2B5-41DB-B6B8-24FD27CE51F3Q36353364-F32EBA5C-E73F-4791-B8A7-4B8745386C4FQ36802016-5818503B-37A5-4247-AC2F-15C3778B6FC1Q36825917-CA0DDA78-9D78-401B-91A1-8600E8048BDDQ36827612-7FA508A2-09BE-442C-B2D9-C0CF46AE0660Q36852943-971F46C7-E029-40E2-8CBA-43FDCDCD913EQ36854824-DD47F53D-4194-4B9B-B80C-39D6F06319C5Q36864290-50A3A9D4-1434-4A13-8449-85B9CBC46208Q36866689-BFBE19F0-8173-4FAC-9DDC-6340B41F11AAQ36868575-8CA218B4-9AD6-41B3-AA36-65082EF49FDDQ36872389-B5C96853-9DC3-43DE-B960-9843FD3021ECQ36872453-BBCF9514-8F84-4C4C-A80F-5E3C344697BCQ36883752-3BB0F2A9-4156-428A-88ED-E6A36AD2B6F6Q36892657-907042A5-B473-43A1-92C2-D0A0C41D2B08Q36898964-37BDAAF5-0528-4676-B542-3B0471576844Q36903869-D385DCFB-E265-46A2-9421-F555D3264464Q36910738-04FE0495-169D-4A09-BF00-76E8BA8FEC3CQ36916007-A66C10C1-E85C-4383-A94B-73405689D970Q36917531-FA140CBC-2EED-482A-9B0E-E0C7C15F2512Q36918805-3A435772-5480-4594-8441-2DFB4D436EA0Q37099580-C9D73038-C1E1-406D-B68E-2911BB2F2C2BQ37109269-880E7505-71BE-472D-8726-843F7FE83B84Q37110564-B726AA05-9C4E-4AD7-9D3B-45F59B44389BQ37110812-EB8ED3A6-862D-440A-B574-919FB487561E
P2860
Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh
1981年學術文章
@zh-hant
name
Use of monoclonal antibody dir ...... s-induced neurological disease
@ast
Use of monoclonal antibody dir ...... s-induced neurological disease
@en
type
label
Use of monoclonal antibody dir ...... s-induced neurological disease
@ast
Use of monoclonal antibody dir ...... s-induced neurological disease
@en
prefLabel
Use of monoclonal antibody dir ...... s-induced neurological disease
@ast
Use of monoclonal antibody dir ...... s-induced neurological disease
@en
P2093
P2860
P1476
Use of monoclonal antibody dir ...... s-induced neurological disease
@en
P2093
P2860
P304
P407
P577
1981-10-01T00:00:00Z